Stock DMAC DIAMEDICA THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus DiaMedica Therapeutics Inc.

Equities

DMAC

CA25253X2077

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
2.9 USD +4.69% Intraday chart for DiaMedica Therapeutics Inc. +0.69% +2.11%
May. 23 DiaMedica Therapeutics Inc. Elects Rick Pauls as Director CI
May. 09 Transcript : DiaMedica Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024

Evolution of the average Target Price on DiaMedica Therapeutics Inc.

Price target over the last 5 years

History of analyst recommendation changes

1da58c3ffb5060153fe6135d125b.e6zJSOlO2wzDflvurK2Q9oG4QyF-CPQUHvn3jDk3TFs.F_j5DYMJnGCOKBjelPzchMaOFhAJcYZaeJy83n5HADcdwYsM2TqBX40rLA~b977d7c8f445500d25e5ce246afb0b0b

Analyst Recommendations on DiaMedica Therapeutics Inc.

Craig Hallum Cuts DiaMedica Therapeutics Price Target to $8 From $11, Maintains Buy Rating MT
Oppenheimer Trims DiaMedica Therapeutics Price Target to $6 From $7, Maintains Outperform Rating MT
Oppenheimer Upgrades DiaMedica Therapeutics to Outperform From Perform, $7 Price Target MT
Oppenheimer Downgrades DiaMedica Therapeutics to Market Perform From Outperform MT
Lake Street Trims DiaMedica Therapeutics' Price Target to $8 From $14, Keeps Buy Rating MT
Craig Hallum Lowers DiaMedica Therapeutics' Price Target to $12 From $18, Keeps Buy Rating MT
Roth Lowers Price Target for DiaMedica Therapeutics to $16 From $24, Maintains Buy Rating MT
Oppenheimer Adjusts DiaMedica Therapeutics' Price Target to $15 From $17, Maintains Outperform Rating MT
Maxim Group Adjusts DiaMedica Therapeutics Price Target to $6 From $11, Maintains Buy Rating MT
Oppenheimer Adjusts DiaMedica Therapeutics PT to $17 From $21, Maintains Outperform Rating MT
DIAMEDICA THERAPEUTICS : Roth Capital Adjusts DiaMedica Therapeutics PT to $24 From $32, Maintains Buy Rating MT
DIAMEDICA THERAPEUTICS : Maxim Group Adjusts Price Target on DiaMedica Therapeutics to $11 From $14, Reiterates Buy Rating MT
DIAMEDICA THERAPEUTICS : Roth Capital Adjusts DiaMedica Therapeutics' Price Target to $32 From $38, Maintains Buy Rating MT
DIAMEDICA THERAPEUTICS : Oppenheimer Starts DiaMedica Therapeutics at Outperform With $27 Price Target MT
DIAMEDICA THERAPEUTICS : Craig-Hallum Adjusts Price Target on DiaMedica Therapeutics to $20 From $15, Maintains Buy Rating MT
DIAMEDICA THERAPEUTICS : Roth Capital Initiates Coverage on DiaMedica Therapeutics at Buy, Sets Price Target at $38 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.9 USD
Average target price
7 USD
Spread / Average Target
+141.38%
High Price Target
8 USD
Spread / Highest target
+175.86%
Low Price Target
6 USD
Spread / Lowest Target
+106.90%

Consensus detail

Consensus revision (last 18 months)

Analysts covering DiaMedica Therapeutics Inc.

Oppenheimer
Craig-Hallum
Lake Street
Roth Capital Partners
Maxim

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. DMAC Stock
  4. Consensus DiaMedica Therapeutics Inc.